Cargando…

An open-label phase I dose-finding study of APR-246 in hematological malignancies

Detalles Bibliográficos
Autores principales:	Deneberg, S, Cherif, H, Lazarevic, V, Andersson, P-O, von Euler, M, Juliusson, G, Lehmann, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5141349/ https://www.ncbi.nlm.nih.gov/pubmed/27421096 http://dx.doi.org/10.1038/bcj.2016.60

Ejemplares similares

Antitumor Effects of PRIMA-1 and PRIMA-1(Met) (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?
por: Menichini, Paola, et al.
Publicado: (2021)

APR-246 Enhances Colorectal Cancer Sensitivity to Radiotherapy
por: Xie, Xuqin, et al.
Publicado: (2023)

APR-246 increases tumor antigenicity independent of p53
por: Michels, Judith, et al.
Publicado: (2023)

APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
por: Mohell, N, et al.
Publicado: (2015)

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
por: Sallman, David A., et al.
Publicado: (2021)

The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells
por: Wang, Zilu, et al.
Publicado: (2023)

APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
por: Zhang, Qiang, et al.
Publicado: (2018)

APR-246 induces early cell death by ferroptosis in acute myeloid leukemia
por: Birsen, Rudy, et al.
Publicado: (2021)

Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors
por: Park, H., et al.
Publicado: (2022)

Correction to: The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells
por: Wang, Zilu, et al.
Publicado: (2023)

Correction: APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
por: Zhang, Qiang, et al.
Publicado: (2019)

Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma
por: Müller, Michael, et al.
Publicado: (2021)

Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma
por: Aryee, D N T, et al.
Publicado: (2013)

Mutant p53 gain of function mediates cancer immune escape that is counteracted by APR-246
por: Zhou, Xiaolei, et al.
Publicado: (2022)

Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246
por: Haffo, Lena, et al.
Publicado: (2018)

Improvement of epidermal covering on AEC patients with severe skin erosions by PRIMA-1(MET)/APR-246
por: Aberdam, Edith, et al.
Publicado: (2020)

Transketolase regulates sensitivity to APR-246 in p53-null cells independently of oxidative stress modulation
por: Milne, Julia V., et al.
Publicado: (2021)

A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
por: Dawson, Mark A., et al.
Publicado: (2023)

Synergistic effects of PRIMA-1(Met) (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia
por: Maslah, Nabih, et al.
Publicado: (2020)

Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy
por: Bykov, Vladimir J. N., et al.
Publicado: (2016)

Piperlongumine and p53-Reactivator APR-246 Selectively Induce Cell Death in HNSCC by Targeting GSTP1
por: Hang, Wei, et al.
Publicado: (2018)

The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells
por: Synnott, Naoise C., et al.
Publicado: (2018)

An open-label, multicohort Phase Ib trial of pembrolizumab (MK-3475) for advanced hematologic malignancies: KEYNOTE-013
por: Ribrag, Vincent, et al.
Publicado: (2015)

P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES
por: Joffe, E., et al.
Publicado: (2022)

APR-246/PRIMA-1(MET) inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase
por: Peng, X, et al.
Publicado: (2013)

APR-246/PRIMA-1(MET) inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase
por: Peng, Xiaoxiao, et al.
Publicado: (2017)

A thiol‐bound drug reservoir enhances APR‐246‐induced mutant p53 tumor cell death
por: Ceder, Sophia, et al.
Publicado: (2020)

PB1913: SYNERGISTIC EFFECTS OF DECITABINE AND APR-246 IN TP53 P.248Q-MUTATED MYELODYSPLASTIC SYNDROME
por: Fang, Y., et al.
Publicado: (2022)

Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade
por: Ghosh, Arnab, et al.
Publicado: (2022)

Immunotherapy against the Cystine/Glutamate Antiporter xCT Improves the Efficacy of APR-246 in Preclinical Breast Cancer Models
por: Barutello, Giuseppina, et al.
Publicado: (2022)

CX-5461 Enhances the Efficacy of APR-246 via Induction of DNA Damage and Replication Stress in Triple-Negative Breast Cancer
por: Makhale, Ashwini, et al.
Publicado: (2021)

Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells
por: Ceder, Sophia, et al.
Publicado: (2021)

APR-246—The Mutant TP53 Reactivator—Increases the Effectiveness of Berberine and Modified Berberines to Inhibit the Proliferation of Pancreatic Cancer Cells
por: McCubrey, James Andrew, et al.
Publicado: (2022)

Abnormal Findings in 246 Consecutive Autopsies on Monkeys
por: Kennard, Margaret A.
Publicado: (1941)

PRIMA-1(met) (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms
por: Li, Xiao-Lan, et al.
Publicado: (2015)

Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53
por: Abrams, Stephen L., et al.
Publicado: (2022)

Correction: Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells
por: Ceder, Sophia, et al.
Publicado: (2022)

Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies
por: Spira, Alexander, et al.
Publicado: (2021)

PARP-1 inhibitors sensitize HNSCC cells to APR-246 by inactivation of thioredoxin reductase 1 (TrxR1) and promotion of ROS accumulation
por: Yin, Zhi-Xian, et al.
Publicado: (2017)

Therapeutic Targeting of P53: A Comparative Analysis of APR-246 and COTI-2 in Human Tumor Primary Culture 3-D Explants
por: Nagourney, Adam J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4iq1m4ge8rbfcbod7si94nn1m2